Armata Pharmaceuticals, Inc.
ARMP · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $5 | $5 | $6 | $4 |
| % Growth | 14.2% | -17.8% | 23.1% | – |
| Cost of Goods Sold | $34 | $1 | $35 | $20 |
| Gross Profit | -$29 | $4 | -$30 | -$16 |
| % Margin | -565.4% | 78.5% | -535.7% | -347.4% |
| R&D Expenses | $34 | $34 | $35 | $20 |
| G&A Expenses | $13 | $0 | $7 | $8 |
| SG&A Expenses | $13 | $11 | $7 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$34 | $0 | -$35 | -$20 |
| Operating Expenses | $13 | $44 | $7 | $8 |
| Operating Income | -$42 | -$41 | -$37 | -$24 |
| % Margin | -820.2% | -902.8% | -670.8% | -532.5% |
| Other Income/Exp. Net | $24 | -$28 | $0 | $1 |
| Pre-Tax Income | -$19 | -$69 | -$37 | -$23 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$19 | -$69 | -$37 | -$23 |
| % Margin | -365.6% | -1,524.5% | -670.2% | -517.5% |
| EPS | -0.523 | -1.91 | -1.08 | -0.96 |
| % Growth | 72.6% | -76.9% | -12.5% | – |
| EPS Diluted | -0.523 | -1.91 | -1.08 | -0.96 |
| Weighted Avg Shares Out | 36 | 36 | 34 | 24 |
| Weighted Avg Shares Out Dil | 36 | 36 | 34 | 24 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $0 | $0 |
| Interest Expense | $11 | $3 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$41 | -$65 | -$36 | -$22 |
| % Margin | -794.6% | -1,445.1% | -654.6% | -490% |